Carnitor Sf

Congenital carnitine deficiency, prophylaxis of Carnitine deficiency, secondary Carnitine deficiency + 2 more
Treatment
5 FDA approvals
20 Active Studies for Carnitor Sf

What is Carnitor Sf

LevocarnitineThe Generic name of this drug
Treatment SummaryChymotrypsin is a substance found in the striated muscles and liver. It is used medicinally to increase the production of digestive juices from the stomach and pancreas. It is also used to treat high levels of fat in the blood.
Carnitoris the brand name
image of different drug pills on a surface
Carnitor Sf Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Carnitor
Levocarnitine
1985
21

Approved as Treatment by the FDA

Levocarnitine, also called Carnitor, is approved by the FDA for 5 uses including secondary Carnitine deficiency and Kidney Failure .
secondary Carnitine deficiency
Kidney Failure
prophylaxis of Carnitine deficiency
Carnitine Deficiency
Congenital carnitine deficiency

Effectiveness

How Carnitor Sf Affects PatientsLevocarnitine is a molecule that helps transport fatty acids in the body, and also helps prevent toxic levels of acyl groups from building up. Not having enough carnitine can lead to liver, heart, and muscle problems. To be deficient in carnitine, there must be abnormally low levels of free carnitine, or a ratio of acylcarnitine to levocarnitine greater than 0.4. The "vitamin BT" form actually contains D,L-carnitine, which can prevent the body from using levocarnitine effectively. Levocarnitine
How Carnitor Sf works in the bodyLevocarnitine is an important molecule that helps the body transport fatty acids and other molecules. It is produced naturally from the amino acids lysine and methionine, with the help of vitamin C. Levocarnitine is handled by different proteins in the body that act as transporters, translocases, acetyltransferases, and palmitoyltransferases. These proteins help move levocarnitine around the body, so fatty acids can be transported safely and efficiently.

When to interrupt dosage

The amount of Carnitor Sf is contingent upon the acknowledged affliction, including prophylaxis of Carnitine deficiency, Kidney Failure and Carnitine Deficiency. The dosage varies, depending on the method of application (e.g. Capsule - Oral or Tablet, film coated) featured in the below table.
Condition
Dosage
Administration
prophylaxis of Carnitine deficiency
1000.0 mg/mL, 250.0 mg/mL, , 330.0 mg, 100.0 mg/mL, 200.0 mg/mL, 500.0 mg, 250.0 mg, 20.0 mg, 300.0 mg, 400.0 mg, 0.012 mg/mg, 1.0 mg/mL, 5.0 mg, 2.1 mg/mg
Injection, Intravenous, Injection - Intravenous, , Oral, Tablet - Oral, Tablet, Solution - Oral, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Lotion - Topical, Injection - Intramuscular, Topical, Lotion, Intramuscular, Tablet, film coated, Tablet, film coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral
secondary Carnitine deficiency
1000.0 mg/mL, 250.0 mg/mL, , 330.0 mg, 100.0 mg/mL, 200.0 mg/mL, 500.0 mg, 250.0 mg, 20.0 mg, 300.0 mg, 400.0 mg, 0.012 mg/mg, 1.0 mg/mL, 5.0 mg, 2.1 mg/mg
Injection, Intravenous, Injection - Intravenous, , Oral, Tablet - Oral, Tablet, Solution - Oral, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Lotion - Topical, Injection - Intramuscular, Topical, Lotion, Intramuscular, Tablet, film coated, Tablet, film coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral
Congenital carnitine deficiency
1000.0 mg/mL, 250.0 mg/mL, , 330.0 mg, 100.0 mg/mL, 200.0 mg/mL, 500.0 mg, 250.0 mg, 20.0 mg, 300.0 mg, 400.0 mg, 0.012 mg/mg, 1.0 mg/mL, 5.0 mg, 2.1 mg/mg
Injection, Intravenous, Injection - Intravenous, , Oral, Tablet - Oral, Tablet, Solution - Oral, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Lotion - Topical, Injection - Intramuscular, Topical, Lotion, Intramuscular, Tablet, film coated, Tablet, film coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral
Kidney Failure
1000.0 mg/mL, 250.0 mg/mL, , 330.0 mg, 100.0 mg/mL, 200.0 mg/mL, 500.0 mg, 250.0 mg, 20.0 mg, 300.0 mg, 400.0 mg, 0.012 mg/mg, 1.0 mg/mL, 5.0 mg, 2.1 mg/mg
Injection, Intravenous, Injection - Intravenous, , Oral, Tablet - Oral, Tablet, Solution - Oral, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Lotion - Topical, Injection - Intramuscular, Topical, Lotion, Intramuscular, Tablet, film coated, Tablet, film coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral
Carnitine Deficiency
1000.0 mg/mL, 250.0 mg/mL, , 330.0 mg, 100.0 mg/mL, 200.0 mg/mL, 500.0 mg, 250.0 mg, 20.0 mg, 300.0 mg, 400.0 mg, 0.012 mg/mg, 1.0 mg/mL, 5.0 mg, 2.1 mg/mg
Injection, Intravenous, Injection - Intravenous, , Oral, Tablet - Oral, Tablet, Solution - Oral, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Lotion - Topical, Injection - Intramuscular, Topical, Lotion, Intramuscular, Tablet, film coated, Tablet, film coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Warnings

Carnitor Sf Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Carnitor Sf.
Common Carnitor Sf Drug Interactions
Drug Name
Risk Level
Description
Revefenacin
Major
Levocarnitine may decrease the excretion rate of Revefenacin which could result in a higher serum level.
(R)-warfarin
Minor
The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Levocarnitine.
(S)-Warfarin
Minor
The therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Levocarnitine.
4-hydroxycoumarin
Minor
The therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Levocarnitine.
Abacavir
Minor
Levocarnitine may decrease the excretion rate of Abacavir which could result in a higher serum level.
Carnitor Sf Toxicity & Overdose RiskThe lowest toxic dose of the drug in mice has been found to be greater than 8g/kg when taken orally. Overdosing on this drug may cause high blood pressure, fever, rapid heartbeat, and seizures.
image of a doctor in a lab doing drug, clinical research

Carnitor Sf Novel Uses: Which Conditions Have a Clinical Trial Featuring Carnitor Sf?

54 active investigations are presently analyzing the potential of Carnitor Sf to address Carnitine Deficiency, Secondary Carnitine Deficiency and Congenital Carnitine Deficiency.
Condition
Clinical Trials
Trial Phases
Kidney Failure
40 Actively Recruiting
Phase 4, Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1
secondary Carnitine deficiency
0 Actively Recruiting
prophylaxis of Carnitine deficiency
0 Actively Recruiting
Congenital carnitine deficiency
0 Actively Recruiting
Carnitine Deficiency
1 Actively Recruiting
Early Phase 1

Carnitor Sf Reviews: What are patients saying about Carnitor Sf?

5Patient Review
12/14/2010
Carnitor Sf for Carnitine Deficiency
This medication has been vital to my dialysis treatments, so I was very surprised when Davita announced they would no longer be carrying it.
5Patient Review
10/2/2010
Carnitor Sf for Carnitine Deficiency
This has been a game-changer for my dialysis treatment.
5Patient Review
4/28/2009
Carnitor Sf for Carnitine Deficiency
This drug was really effective in increasing my energy levels.
5Patient Review
12/14/2010
Carnitor Sf for Carnitine Deficiency
This medication has been vital for my dialysis treatments, so I'm very confused and concerned as to why Davita is no longer carrying it.
5Patient Review
4/28/2009
Carnitor Sf for Carnitine Deficiency
I found that this drug helped to increase my energy levels.
5Patient Review
10/2/2010
Carnitor Sf for Carnitine Deficiency
This has been a game-changer for my dialysis treatments.

Patient Q&A Section about carnitor sf

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

When should I take my Carnitor tablet?

"This product should be taken with food and chewed thoroughly before swallowing. The dose and duration should be as advised by your doctor. Do not start or stop taking this medicine without a doctor's prescription."

Answered by AI

Is carnitine same as Carnitor?

"There is only one FDA-approved medication for treating carnitine deficiency, which is levocarnitine (Carnitor). Carnitine is a substance that occurs naturally in our bodies and helps us to create energy. Levocarnitine (Carnitor) is available both with a prescription and over-the-counter (as l-carnitine)."

Answered by AI

What is Carnitor used for?

"This medication is a diet supplement used to prevent and treat low blood levels of carnitine. Carnitine is a substance made in the body from meat and dairy products. It is also available as a supplement. It helps the body use certain chemicals (long-chain fatty acids) for energy and to keep you in good health."

Answered by AI

Is levocarnitine a steroid?

"Levocarnitine is a protein made from the amino acids lysine and methionine that helps in transporting fats to the cells to be metabolized for energy. It is used to treat primary and secondary levocarnitine deficiency."

Answered by AI

Clinical Trials for Carnitor Sf

Image of New York University Langone Health in New York, United States.

GGTA1 KO Thymokidney for Kidney Failure

40 - 70
All Sexes
New York, NY
The purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2). The study consists of xenotransplantation followed by a 24-week Post-transplant Follow-up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, GGTA1 KO Thymokidney survival, and screening for zoonotic infections. Part B will continue for the lifetime of the participant or for 52 weeks following nephrectomy, if required.
Phase 1 & 2
Recruiting
New York University Langone HealthUnited Therapeutics
Image of Rocky Mountain Kidney Care - Lone Tree in Lone Tree, United States.

AP301 for High Phosphate Levels

Any Age
All Sexes
Lone Tree, CO
The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate. The main questions it aims to answer are: * Does AP301 lower blood phosphate levels? * Does AP301 works on serum calcium level, calcium times phosphate level, and intact parathyroid hormone level? * What discomfort or medical problem do the patients have when taking AP301? * Does AP301 improve quality of life in Chinese patients? The researchers will compare AP301 to an ineffective comparator (a look-alike substance that contains low dose AP301) to see if AP301 works to treat elevated blood phosphate. In the study, the patients will experience the following stages in a chronicle order: * Stop all using blood phosphate-lowering drugs, * Take AP301 or the comparator three times a day for 8 weeks, * Take AP301 three times a day for 24 weeks, and * Take AP301 or the comparator three times a day for 3 weeks. In the first 32 weeks, the dose of AP301 will be adjusted upwards or downwards based on the patient's blood phosphate level and the study doctor's judgment. If the participant has a blood phosphate level above or below a certain level, they may receive additional treatment to lower the blood phosphate level.
Phase 3
Recruiting
Rocky Mountain Kidney Care - Lone Tree (+18 Sites)Alebund Pharmaceuticals
Have you considered Carnitor Sf clinical trials? We made a collection of clinical trials featuring Carnitor Sf, we think they might fit your search criteria.Go to Trials
Image of University Hospital Dialysis Medical Center (DMC) in San Antonio, United States.

Bupropion for Fatigue in Kidney Failure

25 - 74
All Sexes
San Antonio, TX
Fatigue is the most common symptom reported by end-stage kidney disease patients on maintenance hemodialysis. Unfortunately, there currently is no medical management for this overwhelming feeling of tiredness. As a result, patients continue to suffer with poor quality of life and impaired daily activities. The purpose of this pilot trial is to find out if bupropion (a medicine commonly prescribed for stopping smoking, seasonal mood disorder, and depression) may help lessen fatigue in hemodialysis patients. In this study, hemodialysis participants will receive bupropion tablet orally three times a week during routine dialysis procedure for consecutive 8 weeks. Study participants will complete a battery of questionnaires to self-report fatigue, cognition, and quality of life. The study team will collect biological specimens. All these procedures will be performed at the dialysis clinic during routine dialysis procedure.
Phase 1 & 2
Recruiting
University Hospital Dialysis Medical Center (DMC)Subrata Debnath, MB.BS, Ph.D.
Have you considered Carnitor Sf clinical trials? We made a collection of clinical trials featuring Carnitor Sf, we think they might fit your search criteria.Go to Trials
Image of Cooperman Barnabas Medical Center in Livingston, United States.

Communication Skills Training for Kidney Transplant

18+
All Sexes
Livingston, NJ
The goal of this clinical trial is to understand the communication occurring between Black and Caucasian patients and their transplant providers during transplant evaluation consultations and assess relationships between these communicative elements and patient and provider factors, patient-reported outcomes and living donor transplant outcomes - living donor referrals, evaluations, and transplants. We will use these findings to inform the development of a communication skills training for transplant providers and test the impact of the training on providers' communication about live donor kidney transplants with Black and Caucasian patients and living donor transplant outcomes. The main questions it aims to answer are: * How does the use of the use of instrumental, relational and affective communication by patients and providers during the transplant consultation differ by patient and provider factors, patient-reported outcomes and patient ethnicity? * What elements of instrumental, relational and affective communication will be predictive of live donor kidney transplant (LDKT) process outcomes (LD inquiries and evaluations, and actual LDKTs)? Participants will be asked to complete brief surveys before and after the transplant consultation and to give permission for the consultation to be audiorecorded. This data will be used to develop a training to educate providers on the key communication factors predictive of LDKT process outcomes specific to Black and Caucasian patients, and provide guidance on their application during patient consultations. Researchers will then compare communication and patient-reported and LDKT process outcomes between trained and untrained providers to see whether the training has any effect on living donor inquiries and evaluations, and actual LDKTs.
Waitlist Available
Has No Placebo
Cooperman Barnabas Medical Center (+1 Sites)Francis Weng, MD
Image of Victoria Hospital, London Health Sciences Centre in London, Canada.

Theranova Dialyzer for Kidney Failure

18+
All Sexes
London, Canada
Investigators know that many patients who are on dialysis suffer from burden of unwanted symptoms, which can affect quality of life. The understanding and treatment of symptom burden by healthcare providers is limited and should be recognized as a high priority in the care of the dialysis population. In this study, the investigators will be assessing symptom burden using the London Evaluation of Illness "LEVIL," an application based platform where patients self-report their symptoms with one to three hemodialysis treatments per week for 28 weeks. The investigators would like to compare the currently available dialyzer with a new dialyzer that is capable of removing solutes of higher molecular weight that may or may not cause patients to experience symptoms related to increased amounts of toxins in their blood.
Recruiting
Has No Placebo
Victoria Hospital, London Health Sciences Centre (+1 Sites)Christopher McIntyre, MBBS DMBaxter Healthcare Corporation
Have you considered Carnitor Sf clinical trials? We made a collection of clinical trials featuring Carnitor Sf, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security